Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04291105
Recruitment Status : Recruiting
First Posted : March 2, 2020
Last Update Posted : January 7, 2021
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Vyriad, Inc.

Tracking Information
First Submitted Date  ICMJE February 25, 2020
First Posted Date  ICMJE March 2, 2020
Last Update Posted Date January 7, 2021
Actual Study Start Date  ICMJE April 24, 2020
Estimated Primary Completion Date March 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 28, 2020)
Objective response rate (ORR) per imaging assessment [ Time Frame: within 24 months ]
Percentage of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through disease progression, by investigator review based on RECIST version 1.1
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2020)
  • Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0 [ Time Frame: within 24 months ]
    Safety and tolerability
  • Serum concentration time [ Time Frame: within 24 months ]
    Serum concentration time data using RT-PCR of VSV-IFNβ-NIS and systemic cemiplimab levels
  • To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ [ Time Frame: within 24 months ]
    To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ expression
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Official Title  ICMJE Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Brief Summary This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancers type are NSCLC and melanoma that are progressing on CPI treatment, CPI-naïve HCC, and treatment-naïve Endometrial.
Detailed Description Patients with melanoma will be enrolled into two parallel cohorts; in one cohort (Intravenous melanoma cohort) patients will receive IV VV1 and patients in the other cohort (Intratumoral melanoma cohort) will receive both IV VV1 and Intratumoral VV1; both cohorts will receive IV cemiplimab in combination therapy with VV1 treatment. Patients with NSCLC, HCC or endometrial cancer will receive IV VV1 and IV cemiplimab combination therapy.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Melanoma
  • Hepatocellular Carcinoma
  • Non Small Cell Lung Cancer
  • Endometrial Cancer
Intervention  ICMJE
  • Biological: VV1
    VV1 is to be administered on Day 1
    Other Name: VSV-IFNβ-NIS, Voyager V1
  • Biological: Cemiplimab
    Cemiplimab should be given on Day 1 of each 21-day cycle for up to 2 years
    Other Name: Libtayo
Study Arms  ICMJE
  • Experimental: Melanoma intratumoral
    Melanoma, IV & IT VV1 + cemiplimab Patients will receive both intravenous (IV) VV1 and intratumoral (IT) VV1 on Day 1. Will also receveive an infusion of cemiplimab on Day 1.
    Interventions:
    • Biological: VV1
    • Biological: Cemiplimab
  • Experimental: Melanoma
    Melanoma, IV + cemiplimab Patients will receive both IV VV1 and cemiplimab on Day 1.
    Interventions:
    • Biological: VV1
    • Biological: Cemiplimab
  • Experimental: Hepatocellular carcinoma
    Hepatocellular carcinoma Patients will receive both IV VV1 and cemiplimab on Day 1.
    Interventions:
    • Biological: VV1
    • Biological: Cemiplimab
  • Experimental: Non-small cell lung cancer
    Non-small cell lung cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
    Interventions:
    • Biological: VV1
    • Biological: Cemiplimab
  • Experimental: Endometrial cancer
    Endometrial cancer Patients will receive both IV VV1 and cemiplimab on Day 1.
    Interventions:
    • Biological: VV1
    • Biological: Cemiplimab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 28, 2020)
152
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2023
Estimated Primary Completion Date March 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria

  1. Age ≥18 years on day of signing informed consent.
  2. Specific by tumor cohorts:

    • For the HCC cohort, confirmed diagnosis of inoperable HCC by histology or clinical/radiological criteria. i. No prior therapy with a PD-(L)1 immune checkpoint inhibitor (CPI) (prior sorafenib is permitted). ii. No or one prior line of systemic therapy only. iii. Child Pugh Score A or B7.
    • For the NSCLC cohort, histologically confirmed diagnosis of advanced and/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD(L)1 immune CPI and for which no existing options are felt to provide clinical benefit (only one line of PD-(L)1 therapy is permitted).

    Progression during or following 1 or more prior regimen(s) and no more than 3 prior therapeutic regimens for metastatic disease.

    • For the melanoma cohorts, histologically confirmed diagnosis of advanced and/or metastatic melanoma in which radiological progression has been demonstrated during therapy with a PD(L)1 immune CPI and for which no existing options are considered to provide clinical benefit (only one line of PD(L)1 therapy is permitted). Progression on ipilimumab is not required. Note: For IT melanoma cohort:

      • i. At least one tumor lesion amenable to repeated IT injection via palpation or ultrasound. Injection of deep visceral lesions is not permitted.
      • ii. Agrees to provide a newly obtained biopsy of injected and witness lesions prior to start of study treatment, and to repeat biopsies twice during study treatment, and to providing the acquired tissue for biomarker analysis. Tissue obtained for the biopsy must not be previously irradiated, but a new or progressing lesion in the radiation field is acceptable.
    • For the endometrial cancer cohort, histologically confirmed diagnosis of advanced and/or metastatic endometrioid endometrial adenocarcinoma. Eligible patients will not have had any prior systemic therapy in the metastatic setting.
  3. For patients treated with prior anti-PD-(L)1 therapy:

    • Last dose of anti-PD-(L)1 must be within 12 weeks of initiating study treatment.
    • Patient must have received at least 4 doses on q2w, 3 doses on q3w or 2 doses on q4w schedule of the previous anti-PD-(L)1 therapy.
    • Progression on prior anti-PD-(L)1 therapy must be defined by:
    • Documented radiographic progression on a single radiographic scan, if treatment with anti-PD-(L)1 was ≥ 16 weeks.
    • Documented radiographic progression on two consecutive radiographic scans at least 4 weeks apart, if treatment with anti-PD-(L)1 therapy was between 8 - 16 weeks; if radiographic progression is accompanied with clinical progression, then a single scan assessment may be used.
    • If progression was only in lymph nodes, biopsy to provide histological confirmation of progression in the lymph node is required.
  4. Measurable disease based on RECIST 1.1.

Key Exclusion criteria: Patients meeting any of the following exclusion criteria at screening/Day -1 of first dosing will not be enrolled in the study

  1. Availability of and patient acceptance of an alternative curative therapeutic option.
  2. Recent or ongoing serious infection, including any active Grade 3 or higher per the National Institute of Cancer Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE, v5.0) viral, bacterial, or fungal infection within 2 weeks of registration.
  3. Known seropositivity for and with active infection by the human immunodeficiency virus (HIV).

    • Patients who are seropositive for HIV but are receiving antiviral therapy and show non-detectable viral load and a normal CD4 T cell count for at least 6 months are eligible.

  4. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV). Patients who are hepatitis B surface antigen (HBsAg) negative and HBV viral DNA negative are eligible.

    • Patients who had HBV but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible.
    • Patients who are seropositive because of HBV vaccine are eligible.
  5. Seropositive for and with active viral infection with hepatitis C virus (HCV).

    • Patients who had HCV but have received an antiviral treatment and show no detectable HCV viral DNA for 6 months are eligible.

  6. Known history of active or latent TB (bacillus tuberculosis).
  7. Any concomitant serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months).
  8. Prior therapy within the following timeframe before the planned start of study treatment as follows:

    • Small molecule inhibitors, and/or other investigational agent: ≤ 2 weeks or 5 half-lives, whichever is shorter.
    • Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or other similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
    • Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.
  9. New York Heart Association (NYHA) classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia).
  10. Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.
  11. Immunodeficiency or immunosuppression
  12. History of Grade 3 or 4 immune-mediated adverse reaction to immune CPIs.
  13. Toxicities from previous therapies that have not resolved to a Grade 1 or less.
  14. History of non-infectious pneumonitis that required steroids, or current pneumonitis.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Steve Kaesshaefer +19737152917 steve.kaesshaefer@Bexonclinical.com
Contact: Barbara Duckett 5072890944 bduckett@vyriad.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04291105
Other Study ID Numbers  ICMJE VYR-VSV2-203
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Vyriad, Inc.
Study Sponsor  ICMJE Vyriad, Inc.
Collaborators  ICMJE Regeneron Pharmaceuticals
Investigators  ICMJE
Study Chair: Alice Bexon, MD CMO
Study Director: Naimish Pandya, MD Clinical Lead
PRS Account Vyriad, Inc.
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP